Keyphrases
Non-Hodgkin Lymphoma
100%
Relapsed or Refractory
100%
Chimeric Antigen Receptor T-cell Therapy
100%
B Cells
33%
Malignancy
33%
Clinical Course
33%
Poor Prognosis
33%
Most Common Form
33%
Response Rate
33%
Treatment Paradigms
33%
First-line Therapy
33%
Aggressive B-cell non-Hodgkin Lymphoma
33%
Durable Remission
33%
Initial Treatment
33%
Multiple Priors
33%
B-cell NHL
33%
B-cell non-Hodgkin Lymphoma (B-NHL)
33%
Salvage Chemotherapy
33%
Autologous Stem Cells
33%
Medicine and Dentistry
Non-Hodgkin Lymphoma
100%
B Cell
100%
Chimeric Antigen Receptor T-Cell Immunotherapy
100%
Stem Cell
25%
Disease Course
25%
Cancer
25%
Diseases
25%
Pharmacology, Toxicology and Pharmaceutical Science
Nonhodgkin Lymphoma
100%
Chimeric Antigen Receptor
100%
Chemotherapy
25%
Remission
25%
Disease Course
25%
Diseases
25%